
Oral options not keeping up with biologics
Key Takeaways
- The development of oral treatments for moderate-to-severe psoriasis lags behind biologic therapies, necessitating further advancements.
- Current oral treatments include methotrexate, acitretin, cyclosporine, and apremilast, but long-term safety and efficacy remain concerns.
Researchers analyzed emerging oral drugs for psoriasis and concluded “… the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biologic therapies.
In a
Researchers reviewed oral treatments for moderate to severe psoriasis, including methotrexate, acitretin, cyclosporine and apremilast.
Reference
Mahmood T, Zaghi D, Menter A.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.











